Altimmune将出席第18届年度罗德曼全球投资会议

StephenW

Altimmune to Present at 18th Annual Rodman & Renshaw Global Investment Conference

GAITHERSBURG, Md., Aug.  30, 2016  (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference to be held September 11 - 13, 2016 in New York, NY.

  

Bill Enright, Chief Executive Officer, is scheduled to present on Tuesday, September 13, 2016 at 10:50 AM ET.

  

About Altimmune
Altimmune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimmune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system.

  

The Company’s most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. The second most advanced product candidate, HepTcell, is being tested as an immunotherapy for patients chronically infected with hepatitis B and has the potential to provide a functional cure. With the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Company is developing a third product candidate, NasoShield, a first-in-class anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. The Company intends to leverage the RespirVec and Densigen platforms to develop additional product candidates for a variety of indications.

  
Contacts:

Bill Enright
President and CEO
Altimmune, Inc.
Phone: 240-654-1450
Email: [email protected]

Investor Relations
Stephanie Carrington
ICR, Inc.
Phone: 646-277-1282
Email: [email protected]

StephenW

Altimmune将出席第18届年度罗德曼全球投资会议

马里兰州盖瑟斯堡，2016年8月30日（GLOBE NEWSWIRE） - Altimmune公司是一家临床分期免疫公司今天宣布，管理层将在第18届年度罗德曼全球投资会议举行9月11日被提交 - 13，2016年在纽约州纽约市。

比尔恩莱特，首席执行官，计划提出在星期二，2016年9月13日在10:50 ET。

关于Altimmune
Altimmune是一家临床阶段的免疫治疗公司专注于产品，以刺激预防和治疗疾病的坚固耐用的免疫应答的发展。公司有两个专有平台技术，RespirVec和Densigen，其每一个已显示激活免疫系统在比传统疫苗明显不同的方式。使用这些技术，Altimmune制订了三个新的临床阶段的候选产品的潜在代表一种全新的方法来利用免疫系统。

该公司的最先进的产品候选人，NasoVAX，是第2阶段准备鼻内交付重组流感疫苗提供了潜在的广泛和快速的保护比传统的流感疫苗显著的优势。第二个最先进产品候选人，HepTcell，被测试为慢性感染乙型肝炎患者的免疫治疗，并具有提供一种功能治愈的可能性。与之相配套的美国生物医学高级研究与发展管理局或巴尔达的，该公司正在开发第三个候选产品，NasoShield，创一流的炭疽疫苗设计了一个鼻腔给药后提供快速，稳定的保护。本公司拟利用RespirVec和Densigen平台开发更多的产品候选人为各种适应症。

联系方式：

比尔恩莱特
总裁兼首席执行官
Altimmune公司
电话：240-654-1450
电子邮件：enright@alt​​immune.com

投资者关系
斯蒂芬妮卡林顿
ICR公司
电话：646-277-1282
电子邮件：[email protected]